Brief: Bitnile Holdings Announces Additional Investment In Alzamend
28/04/2022 11:39
April 28 (Reuters) - Alzamend Neuro Inc ALZN.O :
* BITNILE HOLDINGS ANNOUNCES ADDITIONAL INVESTMENT IN ALZAMEND FROM
COMPLETION OF
PHASE 1 FIRST-IN-HUMAN CLINICAL TRIAL FOR AL001 TREATMENT OF DEMENTIA RELATED TO
ALZHEIMER’S
Source text for Eikon: ID:nBw76m0bFa
Further company coverage: ALZN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alzamend Neuro
See all newsAlzamend Neuro Inc reports results for the quarter ended April 30 - Earnings Summary
Alzamend Neuro Inc expected to post a loss of 23 cents a share - Earnings Preview
Alzamend Neuro Inc expected to post a loss of 56 cents a share - Earnings Preview
Alzamend Neuro Inc reports results for the quarter ended April 30 - Earnings Summary
Alzamend Neuro Inc expected to post a loss of 67 cents a share - Earnings Preview